热门资讯> 正文
Vertex为Alyfrek囊性纤维化治疗获得NHS英格兰报销协议
2025-07-15 14:18
- Vertex Pharmaceuticals (NASDAQ:VRTX) has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicine, Alyftrek.
- This agreement comes as the National Institute for Health and Care Excellence has issued a positive final draft recommendation for this medicine.
- This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
- Following the European regulatory approval, eligible patients in Ireland, Denmark, and Germany will be the first ones to access deutivacaftor/tezacaftor/vanzacaftor in the European Union.
- Vertex will continue to work with reimbursement bodies across the European Union member states to ensure access for all eligible patients as quickly as possible.
More on Vertex Pharmaceuticals
- Why Vertex Pharmaceuticals Continues To Outperfrom
- Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
- ADA IR Presentation_v FINAL PDF
- Vertex unveils longer-term data on Casgevy
- Vertex gets EU nod for Alyftrek
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。